聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗HBeAg阳性慢性乙型肝炎的随机对照试验(PEGON)
PEGON随机对照试验纳入HBeAg阳性、经恩替卡韦/替诺福韦治疗>12个月且HBV DNA<2000 IU/mL的代偿期肝病患者,比较48周聚乙二醇干扰素α-2b联合治疗与继续核苷(酸)类似物单药治疗的疗效。
要点
- 第48周应答者第72周停用NA后,75%(6/8)维持应答至第96周。
核心结论
- 主要终点为阴性,但聚乙二醇干扰素α-2b联合治疗在干扰素初治的核苷(酸)类似物治疗患者中HBeAg血清学转换频率可能更高。
研究设计与样本
- 随机对照试验,纳入HBeAg阳性代偿期肝病且经恩替卡韦/替诺福韦治疗>12个月、HBV DNA<2000 IU/mL的患者,按1:1随机分配至48周聚乙二醇干扰素α-2b联合治疗组(n=39)或继续核苷(酸)类似物单药治疗组(n=38)。
主要发现
- 第48周8例应答者于第72周停用核苷(酸)类似物,6例(75%)维持应答至第96周(联合组4/6[67%] vs 单药组2/2[100%],P=1.00)。
- 不良事件主要与聚乙二醇干扰素相关。
关键数值与推荐
- 应答定义为HBeAg血清学转换且HBV DNA<200 IU/mL,第48周评估,应答者第72周停用核苷(酸)类似物。
- 主要终点为第96周应答。
临床怎么用
- 对于经核苷(酸)类似物治疗且HBV DNA<2000 IU/mL的HBeAg阳性干扰素初治患者,可考虑聚乙二醇干扰素α-2b联合治疗以提高HBeAg血清学转换机会。
- 联合治疗期间需关注聚乙二醇干扰素相关不良事件。
局限性
- 主要终点未达到统计学显著性。
- 干扰素初治亚组分析样本量较小(58例),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy. METHODS: This randomized trial included HBeAg-positive patients with compensated liver disease who were treated with entecavir/tenofovir for >12 months and had an HBV DNA load of <2000 IU/mL. Patients were randomly assigned in a 1:1 ratio to 48 weeks of peginterferon add-on therapy (n = 39) or continued NA monotherapy (n = 38). Response (defined as HBeAg seroconversion with an HBV DNA load of <200 IU/mL) was assessed at week 48, with responders discontinuing NA therapy at week 72. RESULTS: The primary end point (response at week 96) was achieved in 18% of patients who were assigned peginterferon add-on therapy versus 8% of patients assigned NA monotherapy (P = .31). Among 58 interferon-naive patients, add-on therapy led to a greater frequency of HBeAg seroconversion (30% vs 7%; P = .034) and response (26% vs 7%; P = .068) at week 96, compared with monotherapy. Among 8 responders at week 48 who discontinued NA therapy at week 72, 6 patients (75%) maintained a response until week 96 (4 of 6 [67%] in the add-on therapy group vs 2 of 2 [100%] in the monotherapy group; P = 1.00). Adverse events were mainly related to peginterferon. CONCLUSION: The primary end point was negative, but peginterferon add-on therapy appeared to result in a greater frequency of HBeAg seroconversion, compared with NA monotherapy, in interferon-naive patients receiving NA therapy. CLINICAL TRIALS REGISTRATION: NCT01532843.
引用
- Chi H, Hansen BE, Guo S, et al. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). J Infect Dis. 2017. PMID: 28329061. doi:10.1093/infdis/jix024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。